Kenvue Inc. logo

Kenvue Inc. (1KVUE)

Market Closed
27 Aug, 15:30
XMIL XMIL
16. 48
0
0%
- Market Cap
21.62 P/E Ratio
0.83% Div Yield
150 Volume
1.14 Eps
16.48
Previous Close
Add Transaction
Day Range
16.48 16.48
Year Range
12.16 19.02
Want to track 1KVUE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1KVUE closed Thursday higher at €16.48, an increase of 0% from Wednesday's close, completing a monthly decrease of -0.453% or -€0.07. Over the past 12 months, 1KVUE stock gained 12.2769%.
1KVUE pays dividends to its shareholders, with the most recent payment made on Aug 26, 2026. The next estimated payment will be in In 2 months on Nov 26, 2026 for a total of €0.21.
The last earnings report, released on May 14, 2026, missed the consensus estimates by -0.2633%. On average, the company has fell short of earnings expectations by -0.1911%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NYSE (USD).

1KVUE Chart

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Kimberly-Clark has asked EU regulators permission ​for its proposed $40 billion takeover ‌of Tylenol maker Kenvue, documents on the EU ​Commission's website showed.

Reuters | 4 days ago
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects

Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects

KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.

Zacks | 2 weeks ago
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy

Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy

Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.

Seekingalpha | 2 weeks ago

Kenvue Inc. (1KVUE) FAQ

What is the stock price today?

The current price is €16.48.

On which exchange is it traded?

Kenvue Inc. is listed on XMIL.

What is its stock symbol?

The ticker symbol is 1KVUE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.83%.

What is its market cap?

As of today, no market cap data is available.

Has Kenvue Inc. ever had a stock split?

No, there has never been a stock split.

Kenvue Inc. Profile

Household Products Industry
Consumer Staples Sector
Kirk L. Perry CEO
XMIL Exchange
US49177J1025 ISIN
US Country
21,890 Employees
12 Aug 2026 Last Dividend
- Last Split
4 May 2023 IPO Date

Overview

Kenvue Inc. is a global consumer health firm that offers a wide range of healthcare products through its diverse operational segments: Self Care, Skin Health and Beauty, and Essential Health. Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue Inc. delivers a comprehensive portfolio of products designed to improve the wellness and health of consumers around the world. By leveraging well-known brands across its segments, Kenvue provides solutions for everyday health concerns, from pain relief and cold prevention to skincare and baby care.

Products and Services

  • Self Care: This segment encompasses products for cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and more. Notable brands include Tylenol for pain relief, Motrin for inflammation, Benadryl for allergies, Nicorette for smoking cessation, Zarbee's and ORSLTM for general wellness, Rhinocort for nasal congestion, Calpol for children's fever and pain, and Zyrtec for 24-hour allergy relief.
  • Skin Health and Beauty: Dedicated to maintaining skin health and enhancing beauty, this segment offers products for face and body care, hair care, sun protection, and more. It includes Neutrogena for skincare and acne treatment, Aveeno for moisturizers with natural ingredients, Dr.Ci:Labo for innovative skin solutions, Le Petit Marseillais for shower gels and soaps with enchanting fragrances, Lubriderm for daily moisture, Rogaine for hair regrowth, and OGX for salon-inspired hair care.
  • Essential Health: Focusing on essential healthcare needs, this segment provides oral care, baby care, women's health, wound care, among other products. It features Listerine for oral health, Johnson's products for baby care, Band-Aid for wound protection, Stayfree pads, o.b. tampons, and Carefree liners for feminine hygiene, as well as Desitin Diaper Rash cream to soothe and protect infants.

Contact Information

Address: 1 Kenvue Way
Phone: 908 874 1200